Genocea's vaccine development pipeline includes a variety of infectious disease targets at varying pre-clinical development stages. Genocea's platform has shown early proof of concept for expression cloning, antigen discovery, and immunogenicity data across bacterial, viral and protozoal targets. Our vaccine candidates in development are:

Chlamydia trachomatis Vaccine
Chlamydia trachomatis is the leading bacterial sexually transmitted disease (STD) in the United States. An estimated 3 million Americans are infected with chlamydia each year. The World Health Organization estimates that approximately 92 million new cases of Chlamydia trachomatis infection occur each year worldwide. Chlamydia infections can progress to serious reproductive complications that cause irreversible damage, including infertility, often occurring "silently" before a woman ever recognizes a problem. Untreated infection can spread and cause pelvic inflammatory disease (PID), which occurs in up to 40% of women with untreated Chlamydia. In the U.S., the annual healthcare costs of chlamydia exceed $2 billion.

Genocea has exclusively licensed over 14 antigens to chlamydia trachomatis discovered in the lab of Darren Higgins, Associate Professor of Microbiology and Molecular Genetics at Harvard Medical School and scientific founder of Genocea.

Streptococcus pneumonia Vaccine
Worldwide, Streptococcus pneumoniae, also known as pneumococcus, is the leading cause of death for children less than the age of five. It is estimated that more than 150 million episodes of pneumonia occur every year among children less than five in developing countries, accounting for more than 95 percent of all new cases worldwide.

Genocea, in partnership with global non-profit organization PATH and Children's Hospital Boston, is identifying Streptococcus pneumoniae antigens for use in a protein-based pneumococcal vaccine. Despite the effectiveness of the conjugate pneumococcal vaccines, problems with this approach remain, as these vaccines are very expensive to make and deliver. Furthermore, serotype replacement, which has already been demonstrated in several clinical trials and epidemiologic studies, raises the possibility that different formulations of the vaccines will need to be developed, presumably at even higher cost.